The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Open accessAbstract
SUMMARY Background: Iron, from hemolyzed blood, is implicated in secondary injury after intracerebral haemorrhage (ICH). We aimed to evaluate the safety of the iron chelator, Deferoxamine Mesylate (DFO), and whether it merits investigation in a Phase-III study to definitively assess its effectiveness in improving outcomes in ICH patients. Methods: We conducted a multi-center, randomised, double-blind, placebo-controlled, Phase-II trial at 40 hospitals in USA and Canada. Adults (aged 18–80 years) with primary, spontaneous, supratentorial ICH were randomly assigned (1:1) to DFO (32 mg/kg/day) or saline (placebo) infusions for 3 consecutive days, within 24-hours of ICH-onset. Randomisation was done centrally in real-time and treatment allocation was concealed from participants and investigators. Primary outcome was good clinical outcome, defined as modified Rankin Scale (mRS) score 0–2 at day-90. We performed a futility analysis; if the 90% upper confidence bound (90%UCB) on the absolute risk difference in good outcome proportions is <12% in favour of DFO, then it would be futile to move to Phase-III. Outcome and safety data were analysed based on modified intention-to-treat. (ClinicalTrials.gov Identifier:NCT02175225). Findings: We recruited 294 participants between November 23, 2014 and November 10, 2017. Three were post-randomisation failure; 291 were included in the analyses (144 randomised to DFO; 147 to placebo). Primary outcome was assessed for 283 (97.3%) participants. At day-90, 48/140 (34.3%) of DFO- and 47/143 (32.9%) of placebo-treated subjects had mRS 0–2 (adjusted absolute risk difference 0.6%; 90%UCB 6.8%). By day-90, 70 serious adverse events were reported in 39/144 (27.1%) DFO group and 78 in 49/174 (33.3%) placebo-treated subjects. Death occurred in 10 (6.9%) DFO- and 11 (7.5%) placebo-subjects; none was treatment-related. Interpretation: DFO was safe. The primary result showed it would be futile to further study the effectiveness of DFO with anticipation that it would significantly improve the chance of good outcome (mRS 0–2) at day-90.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions
Magid-Bernstein, J., Girard, R., Polster, S., Srinath, A., Romanos, S., Awad, I. A., & Sansing, L. H. (2022) · Circulation Research · doi:10.1161/circresaha.121.319949 · Cited by 666
Intracerebral hemorrhage: an update on diagnosis and treatment
Hostettler, I. C., Seiffge, D. J., & Werring, D. J. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1623671 · Cited by 341
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation
Xue, M., & Yong, V. W. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30364-1 · Cited by 323
Puy, L., Parry-Jones, A. R., Sandset, E. C., Dowlatshahi, D., Ziai, W., & Cordonnier, C. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00424-7 · Cited by 323
Metadata
- Authors
- Selim, M., Foster, L. D., Moy, C. S., Xi, G., Hill, M. D., Morgenstern, L. B., Greenberg, S. M., James, M. L., Singh, V., Clark, W. M., Norton, C., Palesch, Y. Y., Yeatts, S. D., Dolan, M., Yeh, E., Sheth, K., Kunze, K., Muehlschlegel, S., Nieto, I., Claassen, J., Falo, C., Huang, D., Beckwith, A., Messe, S., Yates, M., O'Phelan, K., Escobar, A., Becker, K., Tanzi, P., Gonzales, N., Tremont, C., Venkatasubramanian, C., Thiessen, R., Save, S., Verrault, S., Collard, K., DeGeorgia, M., Cwiklinski, V., Thompson, B., Wasilewski, L., Andrews, C., Burfeind, R., Torbey, M., Hamed, M., Butcher, K., Sivakumar, L., Varelas, N., Mays-Wilson, K., Leira, E., Olalde, H., Silliman, S., Calhoun, R., Dangayach, N., Renvill, R., Malhotra, R., Kordesch, K., Lord, A., Calahan, T., Geocadin, R., Parish, M., Frey, J., Harrigan, M., Leifer, D., Mathias, R., Schneck, M., Bernier, T., Gonzales-Arias, S., Elysee, J., Lopez, G., Volgi, J., Brown, R., Jasak, S., Phillips, S., Jarrett, J., Gomes, J., McBride, M., Aldrich, F., Aldrich, C., Kornbluth, J., Bettle, M., Goldstein, J., Tirrell, G., Shaw, Q., & Jonczak, K.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 18
- Issue
- 5
- Pages
- 428-438
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2921259698
- Cited by
- 252
- References
- 1
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30069-9
- The paper
- Selim, M., Foster, L. D., Moy, C. S., Xi, G., Hill, M. D., Morgenstern, L. B., Greenberg, S. M., James, M. L., Singh, V., Clark, W. M., Norton, C., Palesch, Y. Y., Yeatts, S. D., Dolan, M., Yeh, E., Sheth, K., Kunze, K., Muehlschlegel, S., Nieto, I., . . . Jonczak, K. (2019). Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30069-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.